In the past week, Immuneering’s shares have plunged 70.9% compared with the industry’s 2.1% fall. This downside came after the company reported topline results from the phase I portion of the ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for ...

The recent 10% drop in Immuneering Corporation's (NASDAQ:IMRX) stock could come as a blow to insiders who purchased US$478.0k worth of stock at an average buy price of US$2.43 over the past 12 months.

Meetings to be held March 10-11 hosted by Oppenheimer. Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Immuneering has a 12-month low of $1.00 and a 12-month high of $7.68. The company has a market capitalization of $51.70 million, a P/E ratio of -0.85 and a beta of -0.36. Get Immuneering alerts: ...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease ...

Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans. Vandana Singh Why Are Amicus, Immunocore ...

Short interest in Immuneering Corp (NASDAQ:IMRX) decreased during the last reporting period, falling from 2.16M to 1.74M. This put 7.4% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...